Under a deal struck by Johnson & Johnson and the Stop TB Partnership, generic versions of J&J’s Sirturo (bedaquiline) tuberculosis treatment will be able to be supplied in low-and middle-income countries despite existing intellectual property for the brand.
Announcing the agreement – which came “following lengthy negotiations” – the Stop TB Partnership, which is a United Nations hosted...





